Skip to main content
PW Medtech Group Limited logo

PW Medtech Group Limited — Investor Relations & Filings

Ticker · 1358 ISIN · KYG7306W1087 LEI · 894500L18EYHNJR6VJ41 HKEX Manufacturing
Open in API
Filings indexed 765 across all filing types
Latest filing 2026-01-30 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1358

About PW Medtech Group Limited

http://www.pwmedtech.com

PW Medtech Group Limited is a medical device company engaged in the research, development, production, and sale of advanced infusion therapy products. The company's core portfolio includes specialized infusion sets and related accessories, such as non-PVC and DEHP-free infusion systems, precision filter infusion sets, light-resistant infusion sets, and safety IV catheters. Operating primarily in China, India, the Americas, and Africa, the Group emphasizes patient and clinician safety. Key innovations include positive pressure needleless connectors designed to prevent blood backflow and contamination, and safety-engineered devices utilizing double-layer tubing (TPU/PVC) and high-precision filtration to mitigate needlestick injuries and adverse infusion reactions.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It details specific share repurchase activities (buybacks) conducted by the issuer, PW Medtech Group Limited, on 30 January 2026. According to the filing definitions, reports of a company buying back its own shares are classified as 'Transaction in Own Shares' (POS).
2026-01-30 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It details specific share repurchase activities (Section II) and confirms compliance with listing rules regarding share capital changes. This type of filing is a standard regulatory requirement for Hong Kong-listed companies to report share buybacks and capital changes, which falls under the 'Transaction in Own Shares' category.
2026-01-28 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Stock Exchange of Hong Kong. It details specific share repurchase activities (buybacks) conducted by the issuer, PW Medtech Group Limited, on 27 January 2026. According to the filing definitions, documents reporting the company buying back its own shares are classified as 'Transaction in Own Shares' (POS).
2026-01-27 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Stock Exchange of Hong Kong. It details specific share repurchase activities (buybacks) by PW Medtech Group Limited. According to the provided definitions, reports of a company buying back its own shares are classified as 'Transaction in Own Shares' (POS).
2026-01-26 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for companies listed on the HKEX to report monthly movements in their securities, including share capital, issued shares, and treasury shares. Since it is a recurring regulatory filing regarding share capital and movements, it falls under the 'Regulatory Filings' category.
2026-01-05 English
VOLUNTARY ANNOUNCEMENT - PROGRESS ON THE SUBSEQUENT LISTING OF SICHUAN RUIJIAN MEDICAL ON BEIJING STOCK EXCHANGE
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by PW Medtech Group Limited regarding the progress of a subsidiary's (Sichuan Ruijian Medical) listing process on the Beijing Stock Exchange. It provides updates on the suspension and subsequent resumption of the review process. As it is a general regulatory announcement regarding corporate developments that does not fit into specific categories like M&A (it is a listing update, not a takeover bid) or financial reports, it is classified as a Regulatory Filing (RNS).
2025-12-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.